^{67}Ga-Tetraazacyclododecane-*N,N′,N″,N‴*-tetraacetic acid-3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylamine-γ-folate

^{67}Ga-P1254

Kam Leung, PhD[1]

Created: February 14, 2011; Updated: May 26, 2011.

Chemical name:	^{67}Ga-Tetraazacyclododecane-*N,N′,N″,N‴*-tetraacetic acid-3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylamine-γ-folate
Abbreviated name:	^{67}Ga-P1254
Synonym:	
Agent category:	Compound
Target:	Putative folate receptor
Target category:	Receptor
Method of detection:	Single-photon emission computed tomography (SPECT)
Source of signal:	^{67}Ga
Activation:	No
Studies:	• *In vitro* • Rodents



Click on the above structure for additional information in PubChem.

Background

[PubMed]

[1] National Center for Biotechnology Information, NLM, NIH; Email: MICAD@ncbi.nlm.nih.gov.

Corresponding author.

Folic acid (folate) is a water-soluble B vitamin (1) that is essential for methylation and DNA synthesis. The primary pathway for entry of folate into cells is through the facilitated transporter, which has a low affinity for folate (Michaelis constant (K_m) = 1–5 μM). Some cells in the choroid plexus, kidney, lung, thyroid, spleen, placenta, and thymus also possess a higher-affinity (dissociation constant (K_d) = 0.5 nM) receptor that allows folate uptake *via* receptor-mediated endocytosis. Some human epithelial tumor cells have been found to overexpress folate-binding protein (2). More than 90% of human ovarian and endometrial cancers express the high-affinity receptor, which is absent in the corresponding normal tissues. Breast, colorectal, renal, and lung carcinomas also overexpress the folate receptor but at lower frequencies (20%–50%). Activated macrophages, but not resting macrophages, have been also found to have the folate receptor (3).

Several folate-based conjugates (^{111}In-DTPA-folate, ^{99m}Tc-EC-folate, and [^{18}F]FBA-folate) have been studied in tumor imaging (4-8). Deferoxamine (DF), a chelating agent, was conjugated to folic acid forming a mixture of two isomers, DF-α-folate and DF-γ-folate. Only the DF-γ-folate isomer was able to displace [^{3}H]folic acid from its receptors with a 50% inhibition concentration similar to that of folic acid (2.5 nM *versus* 2.4 nM) (9). $^{68/67/66}$Ga-γ-DF-folate is being developed as an imaging agent for the detection of folate receptors *in vivo* with either positron emission tomography or single-photon emission computed tomography. In this chapter, Fani et al. (10) prepared a γ-folate conjugate with tetraazacyclododecane-*N*,*N*′,*N*″,*N*‴-tetraacetic acid (DOTA) and 3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylamine as a spacer to form P1254, which was labeled with ^{67}Ga for detection of folate receptors.

Related Resource Links:

- Chapters in MICAD (folate receptor)
- Gene information in NCBI (folate receptor)
- Articles in OMIM (folate receptor)
- Clinical trials (folate receptors)
- Drug information in FDA (folate receptor)

Synthesis

[PubMed]

NLM Citation: Leung K. ^{67}Ga-Tetraazacyclododecane-*N*,*N*′,*N*″,*N*‴-tetraacetic acid-3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylamine-γ-folate. 2011 Feb 14 [Updated 2011 May 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

Fani et al. (10) coupled P1254 (10 nmol) with 74 MBq (2 mCi) $^{67}GaCl_3$ in acetate buffer (pH 5) for 30 min at 95°C to yield ^{67}Ga-P1254 with >95% radiochemical purity. Radiochemical yield was >95% with a specific activity of 7 MBq/nmol (0.19 mCi/nmol).

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

The human nasopharyngeal carcinoma KB cell line has putative folate receptors as determined with ^{67}Ga-P1254 saturation binding studies at 4°C (10). ^{67}Ga-P1254 showed a K_d (affinity constant) of 4.27 ± 0.42 nM and a B_{max} (receptor density) of 11.45 ± 0.27 nM. There were ~6.9×10^6 folate binding sites per KB cell. ^{67}Ga-P1254 (2.5 nM) was rapidly associated with KB cells at 37°C with 56% of incubation dose (ID) at 30 min and ~70% ID at 4 h. Approximately 12% ID of ^{67}Ga-P1254 was internalized at 4 h. Excess folate blocked the cell-associated radioactivity to <0.5% ID. Approximately 82% of radioactivity was retained in the cells after 4 h incubation in fresh medium.

Animal Studies

Rodents

[PubMed]

Fani et al. (10) performed *ex vivo* biodistribution studies of 1.5 MBq (0.041 mCi, 0.4 nmol) ^{67}Ga-P1254 in nude mice (n = 4–7/group) bearing KB and HT1080 (low folate receptor expression) tumor xenografts. Accumulation of ^{67}Ga-P1254 in the KB tumors was 12.5 ± 1.5, 10.4 ± 0.4, and 13.1 ± 0.7% ID/g at 1, 2, and 4 h after injection, respectively. The accumulation in the HT1080 tumors was 1.3%–2.4% ID/g at these time points. The organ with the highest accumulation at 4 h after injection was the kidney (104.0% ID/g), followed by the adrenal (3.0% ID/g), pancreas (2.8% ID/g), liver (2.2% ID/g), heart (1.9% ID/g), and pituitary (1.7% ID/g). The accumulation in the blood was low (<0.4% ID/g). The tumor/blood ratios were 39, 41, and 63 at 1, 2, and 4 h, respectively. Pretreatment with excess folate (40 nmol, 5 min before injection) reduced the radioactivity accumulation by >90% in the tumors and kidney at 4 h after injection.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

References

1. Stanger O. *Physiology of folic acid in health and disease.* Curr Drug Metab. 2002;3(2): 211–23. PubMed PMID: 12003352.
2. Ke C.Y., Mathias C.J., Green M.A. *The folate receptor as a molecular target for tumor-selective radionuclide delivery.* Nucl Med Biol. 2003;30(8):811–7. PubMed PMID: 14698784.
3. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. *Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis.* Arthritis Rheum. 1999;42(8):1609–16. PubMed PMID: 10446858.
4. Mathias C.J., Hubers D., Low P.S., Green M.A. *Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical.* Bioconjug Chem. 2000;11(2):253–7. PubMed PMID: 10725102.
5. Mathias C.J., Lewis M.R., Reichert D.E., Laforest R., Sharp T.L., Lewis J.S., Yang Z.F., Waters D.J., Snyder P.W., Low P.S., Welch M.J., Green M.A. *Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals.* Nucl Med Biol. 2003;30(7):725–31. PubMed PMID: 14499330.
6. Mathias C.J., Wang S., Low P.S., Waters D.J., Green M.A. *Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor-positive human KB tumor xenografts.* Nucl Med Biol. 1999;26(1):23–5. PubMed PMID: 10096497.
7. Mathias C.J., Wang S., Waters D.J., Turek J.J., Low P.S., Green M.A. *Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical.* J Nucl Med. 1998;39(9):1579–85. PubMed PMID: 9744347.
8. Bettio A., Honer M., Muller C., Bruhlmeier M., Muller U., Schibli R., Groehn V., Schubiger A.P., Ametamey S.M. *Synthesis and Preclinical Evaluation of a Folic Acid Derivative Labeled with 18F for PET Imaging of Folate Receptor-Positive Tumors.* J Nucl Med. 2006;47(7):1153–1160. PubMed PMID: 16818950.
9. Wang S., Lee R.J., Mathias C.J., Green M.A., Low P.S. *Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging.* Bioconjug Chem. 1996;7(1):56–62. PubMed PMID: 8741991.
10. Fani M., Wang X., Nicolas G., Medina C., Raynal I., Port M., Maecke H.R. *Development of new folate-based PET radiotracers: preclinical evaluation of Ga-DOTA-folate conjugates.* Eur J Nucl Med Mol Imaging. 2011;38(1):108–19. PubMed PMID: 20799032.